Coya Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Coya Therapeutics, Inc. (COYA) reported Increase (Decrease) in Prepaid Expense and Other Assets of $640.06 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-11
- Coya Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $1.22M, a 47.19% increase year-over-year.
- Coya Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$578.20K.
- Coya Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$778.71K, a 151.24% decline year-over-year.
- Coya Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $224.63K, a 80.26% decline year-over-year.
- Coya Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$2.85M, a 158.22% decline from fiscal 2024.
- Coya Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $4.90M.
- Coya Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$181.71K, a 119.75% decline from fiscal 2022.
- Coya Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $920.00K, a 324.33% increase from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $640.06K 10-Q · filed 2026-08-11 | -$138.65K derived: sum of 3 quarters · filed 2026-08-11 | $85.97K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$578.20K 10-Q · filed 2026-05-12 | -$1.36M derived: sum of 2 quarters · filed 2026-05-12 | -$1.13M derived: sum of 3 quarters · filed 2026-05-12 | -$304.59K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$778.71K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$554.09K derived: sum of 2 quarters · filed 2026-03-16 | $273.61K derived: sum of 3 quarters · filed 2026-08-11 | -$2.85M 10-K · filed 2026-03-16 |
| 2025-09-30 | $224.63K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.05M derived: sum of 2 quarters · filed 2026-08-11 | -$2.07M 10-Q · filed 2025-11-12 | -$554.06K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $827.70K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$2.30M 10-Q · filed 2026-08-11 | -$778.69K derived: sum of 3 quarters · filed 2026-08-11 | $359.06K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$3.13M 10-Q · filed 2026-05-12 | -$1.61M derived: sum of 2 quarters · filed 2026-05-12 | -$468.63K derived: sum of 3 quarters · filed 2026-05-12 | $1.50M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $2.66M derived: sum of 2 quarters · filed 2026-03-16 | $4.62M derived: sum of 3 quarters · filed 2026-03-16 | $4.90M 10-K · filed 2026-03-16 |
| 2024-09-30 | $1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.10M derived: sum of 2 quarters · filed 2025-11-12 | $3.38M 10-Q · filed 2025-11-12 | $3.51M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $2.24M 10-Q · filed 2025-08-12 | $2.37M derived: sum of 3 quarters · filed 2025-08-12 | $2.02M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $275.40K 10-Q · filed 2025-05-13 | $408.60K derived: sum of 2 quarters · filed 2025-05-13 | $57.74K derived: sum of 3 quarters · filed 2025-05-13 | $332.99K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $133.20K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$217.66K derived: sum of 2 quarters · filed 2025-03-18 | $57.59K derived: sum of 3 quarters · filed 2025-03-18 | -$181.71K 10-K · filed 2025-03-18 |
| 2023-09-30 | -$350.86K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$75.61K derived: sum of 2 quarters · filed 2024-11-06 | -$314.91K 10-Q · filed 2024-11-06 | $881.10K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $275.24K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $35.95K 10-Q · filed 2024-08-12 | $1.23M derived: sum of 3 quarters · filed 2024-08-12 | $1.16M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$239.29K 10-Q · filed 2024-05-09 | $956.72K derived: sum of 2 quarters · filed 2024-05-09 | $884.92K derived: sum of 3 quarters · filed 2024-05-09 | $872.02K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $1.12M derived: sum of 2 quarters · filed 2024-03-19 | $1.11M derived: sum of 3 quarters · filed 2024-03-19 | $920.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | -$71.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$84.70K derived: sum of 2 quarters · filed 2023-11-08 | -$276.01K 10-Q · filed 2023-11-08 | |
| 2022-06-30 | -$12.90K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$204.22K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$191.31K 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $216.81K 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |